- Home
- CTOR vs MGX Comparison
CTOR vs MGX Comparison
Compare CTOR & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- MGX
- Stock Information
- Founded
- CTOR 2021
- MGX 2018
- Country
- CTOR United States
- MGX United States
- Employees
- CTOR N/A
- MGX N/A
- Industry
- CTOR
- MGX
- Sector
- CTOR
- MGX
- Exchange
- CTOR NYSE
- MGX NYSE
- Market Cap
- CTOR 63.7M
- MGX 62.1M
- IPO Year
- CTOR N/A
- MGX 2024
- Fundamental
- Price
- CTOR $1.97
- MGX $2.43
- Analyst Decision
- CTOR Buy
- MGX Strong Buy
- Analyst Count
- CTOR 2
- MGX 4
- Target Price
- CTOR $6.00
- MGX $13.00
- AVG Volume (30 Days)
- CTOR 3.1M
- MGX 1.0M
- Earning Date
- CTOR 08-11-2025
- MGX 08-13-2025
- Dividend Yield
- CTOR N/A
- MGX N/A
- EPS Growth
- CTOR N/A
- MGX N/A
- EPS
- CTOR N/A
- MGX N/A
- Revenue
- CTOR N/A
- MGX $45,263,000.00
- Revenue This Year
- CTOR N/A
- MGX N/A
- Revenue Next Year
- CTOR N/A
- MGX $3.97
- P/E Ratio
- CTOR N/A
- MGX N/A
- Revenue Growth
- CTOR N/A
- MGX N/A
- 52 Week Low
- CTOR $0.55
- MGX $1.23
- 52 Week High
- CTOR $49.00
- MGX $4.92
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- MGX 66.95
- Support Level
- CTOR N/A
- MGX $1.98
- Resistance Level
- CTOR N/A
- MGX $2.64
- Average True Range (ATR)
- CTOR 0.00
- MGX 0.23
- MACD
- CTOR 0.00
- MGX 0.04
- Stochastic Oscillator
- CTOR 0.00
- MGX 77.89
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.